ABP 692 vs Ofatumumab

Same mechanism, same race: design-graded trial evidence for both assets, with the grading rationale shown. Grades describe the quality of the evidence, never the merits of either security.

Multiple Sclerosis

Shared mechanism: CD20 · full Multiple Sclerosis pipeline

ABP 692

Developed by Amgen

Phase 3 in Multiple Sclerosismonoclonal antibody
not yet graded

No graded featured trial for this indication yet; the grade above reflects that absence, not a judgment.

Next expected readout: April 2027 · NCT06700343 (registry estimate)

No aligned efficacy figure on record for this race.

Ofatumumab

Marketed by Novartis and partners

Approved in Multiple Sclerosismonoclonal antibody
Reliable signal

NCT02792231 · Phase 3 · completed

This was a large, randomized, quadruple-blind, active-controlled trial of 955 participants, comparing ofatumumab with teriflunomide. The prespecified primary clinical endpoint, annualized confirmed relapse rate, was significantly better with ofatumumab (p<0.001), supporting a strong evidence grade despite mixed findings for some secondary measures.

Next expected readout: April 2027 · NCT05090371 (registry estimate)

Reported efficacy

Annualized Relapse Rate (ARR) (Baseline up to 2.5 years): Annualized Relapse Rate (ASCLEPIOS II): 0.10 (ofatumumab) vs 0.25 (teriflunomide); difference -0.15 (95% CI: -0.20, -0.09) (met)

Result source: NCT02792231

Results for Multiple Sclerosis

Values come from each drug's own ClinicalTrials.gov study. They are from separate trials and patient populations, not a head-to-head comparison. Each result identifies its source trial, phase, arm and timepoint; limitations that apply to a whole cell are marked with a letter and listed once beneath the table. The comparison is deepest for later-stage drugs (phase 3 or approved), which usually have posted results to draw on; early-stage drugs often have none yet.

Key endpointABP 692Ofatumumab
Annualised relapse rate—Trial running · NCT067003430.1 vs 0.3vs TER20 mg · n 469NCT02792231
4 other results
  • 0.1 vs 0.2 20 mg · n 454 · Phase 3 · primary NCT02792218
  • 0.1 vs 0.2 20 mg · n 461 · Phase 3 · secondary NCT02792231
  • 0.1 vs 0.2 20 mg · n 453 · Phase 3 · secondary NCT02792218
  • 0.3 vs 0.6 20 mg · wk 24 · n 43 · Phase 2 · secondary NCT03249714
Free of 3-month confirmed disability progression (%)—Trial running · NCT06700343—Not posted · NCT04788615
New or enlarging T2 lesions—Trial running · NCT06700343—Not posted · NCT04788615

Annualised relapse rate

ABP 692
—Trial running · NCT06700343
Ofatumumab
0.1 vs 0.3vs TER20 mg · n 469NCT02792231
4 other results
  • 0.1 vs 0.2 20 mg · n 454 · Phase 3 · primary NCT02792218
  • 0.1 vs 0.2 20 mg · n 461 · Phase 3 · secondary NCT02792231
  • 0.1 vs 0.2 20 mg · n 453 · Phase 3 · secondary NCT02792218
  • 0.3 vs 0.6 20 mg · wk 24 · n 43 · Phase 2 · secondary NCT03249714

Free of 3-month confirmed disability progression (%)

ABP 692
—Trial running · NCT06700343
Ofatumumab
—Not posted · NCT04788615

New or enlarging T2 lesions

ABP 692
—Trial running · NCT06700343
Ofatumumab
—Not posted · NCT04788615
  1. Each cell is from that drug's own trial. Trials differ in population, design and timepoint; this is not a head-to-head comparison.
  2. An empty cell names why: Not posted (a completed Phase 3 here has no posted results yet), Trial running, Pending review (we hold the result and are checking it) or Not reported.

ABP 692: no structured comparison results are available for Multiple Sclerosis.

Only safety results can currently be compared in this indication. Reviewed efficacy summaries, where available, are listed separately.

safety

Coverage. ABP 692: 0 of 4 rows · Ofatumumab: 4 of 4 rows. A dash means no reviewed, structured value is available for that endpoint in this indication.

Reported metricOfatumumab
Dropout rate
17%20 mga
NCT02792231 · Phase 3
show 26 more results
—20mg
NCT02792231 · Phase 3
10.5%20 mg
NCT02792218 · Phase 3
—20 mg
NCT02792218 · Phase 3
19.8%20 mg
NCT04486716 · Phase 3
2.9%60 mg q12w
NCT01457924 · Phase 2
9.4%60 mg q4w
NCT01457924 · Phase 2
6.3%30 mg q12w
NCT01457924 · Phase 2
14.7%3 mg q12w
NCT01457924 · Phase 2
0%700 mg
NCT00640328 · Phase 2 · monotherapy
9.1%300 mg
NCT00640328 · Phase 2 · monotherapy
0%100 mg
NCT00640328 · Phase 2 · monotherapy
7.6%Ofatumumab
NCT05084638 · Phase 4 · registry result, not featured evidence
—Ofatumumab-Treated
NCT05084638 · Phase 4 · registry result, not featured evidence
4%
NCT05199571 · Phase 4 · registry result, not featured evidence
—20 mg
NCT04353492 · Phase 3 · registry result, not featured evidence
6.9%Ofatumumab
NCT04353492 · Phase 3 · registry result, not featured evidence
7%20 mg
NCT03249714 · Phase 2 · registry result, not featured evidence
—20 mg
NCT03249714 · Phase 2 · registry result, not featured evidence
—20 mg
NCT03249714 · Phase 2 · registry result, not featured evidence
—20 mg
NCT03560739 · Phase 2 · registry result, not featured evidence
—20 mg
NCT03560739 · Phase 2 · registry result, not featured evidence
0%20 mg
NCT03560739 · Phase 2 · registry result, not featured evidence
0%20 mg
NCT03560739 · Phase 2 · registry result, not featured evidence
—20 mg
NCT03560739 · Phase 2 · registry result, not featured evidence
0.8%20 mg
NCT03560739 · Phase 2 · registry result, not featured evidence
0%20 mg
NCT03560739 · Phase 2 · registry result, not featured evidence
Discontinued due to AEs
3.1%20 mga
NCT02792231 · Phase 3
show 26 more results
—20mg
NCT02792231 · Phase 3
3.2%20 mg
NCT02792218 · Phase 3
—20 mg
NCT02792218 · Phase 3
4.5%20 mg
NCT04486716 · Phase 3
0%60 mg q12w
NCT01457924 · Phase 2
3.1%60 mg q4w
NCT01457924 · Phase 2
3.1%30 mg q12w
NCT01457924 · Phase 2
11.8%3 mg q12w
NCT01457924 · Phase 2
0%700 mg
NCT00640328 · Phase 2 · monotherapy
9.1%300 mg
NCT00640328 · Phase 2 · monotherapy
0%100 mg
NCT00640328 · Phase 2 · monotherapy
—Ofatumumab
NCT05084638 · Phase 4 · registry result, not featured evidence
—Ofatumumab-Treated
NCT05084638 · Phase 4 · registry result, not featured evidence
—
NCT05199571 · Phase 4 · registry result, not featured evidence
—20 mg
NCT04353492 · Phase 3 · registry result, not featured evidence
0.5%Ofatumumab
NCT04353492 · Phase 3 · registry result, not featured evidence
—20 mg
NCT03249714 · Phase 2 · registry result, not featured evidence
—20 mg
NCT03249714 · Phase 2 · registry result, not featured evidence
—20 mg
NCT03249714 · Phase 2 · registry result, not featured evidence
—20 mg
NCT03560739 · Phase 2 · registry result, not featured evidence
—20 mg
NCT03560739 · Phase 2 · registry result, not featured evidence
0%20 mg
NCT03560739 · Phase 2 · registry result, not featured evidence
0%20 mg
NCT03560739 · Phase 2 · registry result, not featured evidence
—20 mg
NCT03560739 · Phase 2 · registry result, not featured evidence
0.8%20 mg
NCT03560739 · Phase 2 · registry result, not featured evidence
0%20 mg
NCT03560739 · Phase 2 · registry result, not featured evidence
Serious AEs
—20 mga
NCT02792231 · Phase 3
show 26 more results
8.7%20mg
NCT02792231 · Phase 3
—20 mg
NCT02792218 · Phase 3
11%20 mg
NCT02792218 · Phase 3
5.9%20 mg
NCT04486716 · Phase 3
2.9%60 mg q12w
NCT01457924 · Phase 2
6.3%60 mg q4w
NCT01457924 · Phase 2
0%30 mg q12w
NCT01457924 · Phase 2
2.9%3 mg q12w
NCT01457924 · Phase 2
0%700 mg
NCT00640328 · Phase 2 · monotherapy
18.2%300 mg
NCT00640328 · Phase 2 · monotherapy
0%100 mg
NCT00640328 · Phase 2 · monotherapy
—Ofatumumab
NCT05084638 · Phase 4 · registry result, not featured evidence
6.7%Ofatumumab-Treated
NCT05084638 · Phase 4 · registry result, not featured evidence
0%
NCT05199571 · Phase 4 · registry result, not featured evidence
6%20 mg
NCT04353492 · Phase 3 · registry result, not featured evidence
—Ofatumumab
NCT04353492 · Phase 3 · registry result, not featured evidence
—20 mg
NCT03249714 · Phase 2 · registry result, not featured evidence
2.5%20 mg
NCT03249714 · Phase 2 · registry result, not featured evidence
2.3%20 mg
NCT03249714 · Phase 2 · registry result, not featured evidence
1.6%20 mg
NCT03560739 · Phase 2 · registry result, not featured evidence
0%20 mg
NCT03560739 · Phase 2 · registry result, not featured evidence
—20 mg
NCT03560739 · Phase 2 · registry result, not featured evidence
—20 mg
NCT03560739 · Phase 2 · registry result, not featured evidence
0%20 mg
NCT03560739 · Phase 2 · registry result, not featured evidence
3.1%20 mg
NCT03560739 · Phase 2 · registry result, not featured evidence
—20 mg
NCT03560739 · Phase 2 · registry result, not featured evidence
Most frequent reported AEs
20mga
injection related reaction 24.7%
injection related reaction 24.7%
nasopharyngitis 18.3%
NCT02792231 · Phase 3
show 18 more results
20 mg
nasopharyngitis 17.6%
injection related reaction 15.9%
headache 12.7%
NCT02792218 · Phase 3
20 mg
covid-19 30.4%
fatigue 11.8%
headache 11.8%
NCT04486716 · Phase 3
60 mg q12w
injection related reaction 50%
nasopharyngitis 20.6%
fatigue 5.9%
NCT01457924 · Phase 2
60 mg q4w
injection related reaction 65.6%
nasopharyngitis 10.9%
headache 9.4%
NCT01457924 · Phase 2
30 mg q12w
injection related reaction 40.6%
nasopharyngitis 12.5%
fatigue 9.4%
NCT01457924 · Phase 2
3 mg q12w
injection related reaction 47.1%
urinary tract infection 8.8%
anaemia 5.9%
NCT01457924 · Phase 2
700 mg
rash 57.1% (placebo 50%)
throat irritation 28.6% (placebo 0%)
upper respiratory tract infection 28.6% (placebo 75%)
NCT00640328 · Phase 2 · monotherapy
300 mg
throat irritation 36.4% (placebo 0%)
rash 27.3% (placebo 50%)
viral infection 27.3% (placebo 0%)
NCT00640328 · Phase 2 · monotherapy
100 mg
nasopharyngitis 50% (placebo 25%)
throat irritation 37.5% (placebo 0%)
depression 25% (placebo 0%)
NCT00640328 · Phase 2 · monotherapy
chills 36.1%
headache 27.7%
myalgia 26.1%
NCT05084638 · Phase 4 · registry result, not featured evidence
injection related reaction 43.4%
covid-19 12.1%
upper respiratory tract infection 12.1%
NCT05199571 · Phase 4 · registry result, not featured evidence
20 mg
injection related reaction 53.4%
covid-19 37%
nasopharyngitis 17.1%
NCT04353492 · Phase 3 · registry result, not featured evidence
20 mg
nasopharyngitis 17.5% (placebo 19%)
rash 7.5% (placebo 0%)
alanine aminotransferase increased 5% (placebo 4.8%)
NCT03249714 · Phase 2 · registry result, not featured evidence
20 mg
injection related reaction 20.9% (placebo 19%)
nasopharyngitis 14% (placebo 19%)
oral herpes 9.3% (placebo 0%)
NCT03249714 · Phase 2 · registry result, not featured evidence
20 mg
injection related reaction 32%
headache 10.2%
injection site reaction 8.6%
NCT03560739 · Phase 2 · registry result, not featured evidence
20 mg
injection related reaction 38.5%
diarrhoea 7.7%
fatigue 7.7%
NCT03560739 · Phase 2 · registry result, not featured evidence
20 mg
injection related reaction 46.2%
asthenia 7.7%
cough 7.7%
NCT03560739 · Phase 2 · registry result, not featured evidence
20 mg
injection related reaction 22.3%
injection site reaction 13.1%
headache 5.4%
NCT03560739 · Phase 2 · registry result, not featured evidence

Notes

  1. aPopulation comparability has not been reviewed for these studies.

Reported by one asset only

Endpoints only one of the selected assets measured, so there is nothing to compare them against.

Ofatumumab

Annualized Relapse 0.1 vs 0.25 TER per year20 mg
event rate · per year
NCT02792231 · Phase 3
show 4 more results
0.096 vs 0.241 TER per year20 mg
NCT02792231 · Phase 3
0.11 vs 0.22 TER per year20 mg
NCT02792218 · Phase 3
0.096 vs 0.242 TER per year20 mg
NCT02792218 · Phase 3
0.264 vs 0.6286 placebo per year @ 24wk20 mg
NCT03249714 · Phase 2 · registry result, not featured evidence
Confirmed Disability Progression 9.4% (n=944) vs 13.5% (n=932) TER @ 78wk20 mg
responder rate · % of participants
NCT02792231 · Phase 3
show 17 more results
10.9% (n=944) vs 15% (n=932) TER @ 104wk20 mg
NCT02792231 · Phase 3
9.3% (n=479) vs 13.2% (n=473) TER @ 78wk20 mg
NCT02792231 · Phase 3
10.5% (n=479) vs 14.6% (n=473) TER @ 104wk20 mg
NCT02792231 · Phase 3
9.4% (n=944) vs 13.5% (n=932) TER @ 78wk20 mg
NCT02792231 · Phase 3
10.9% (n=944) vs 15% (n=932) TER @ 104wk20 mg
NCT02792231 · Phase 3
9.4% (n=944) vs 13.5% (n=932) TER @ 78wk20 mg
NCT02792218 · Phase 3
10.9% (n=944) vs 15% (n=932) TER @ 104wk20 mg
NCT02792218 · Phase 3
9.4% (n=465) vs 13.9% (n=459) TER @ 78wk20 mg
NCT02792218 · Phase 3
11.3% (n=465) vs 15.4% (n=459) TER @ 104wk20 mg
NCT02792218 · Phase 3
7.8% (n=944) vs 10.7% (n=932) TER @ 78wk20 mg
NCT02792218 · Phase 3
8.1% (n=944) vs 12% (n=932) TER @ 104wk20 mg
NCT02792218 · Phase 3
7.5% (n=465) vs 11.5% (n=459) TER @ 78wk20 mg
NCT02792218 · Phase 3
8.2% (n=465) vs 13% (n=459) TER @ 104wk20 mg
NCT02792218 · Phase 3
9.4% (n=944) vs 13.5% (n=932) TER @ 78wk20 mg
NCT02792218 · Phase 3
10.9% (n=944) vs 15% (n=932) TER @ 104wk20 mg
NCT02792218 · Phase 3
7.8% (n=944) vs 10.7% (n=932) TER @ 78wk20 mg
NCT02792218 · Phase 3
8.1% (n=944) vs 12% (n=932) TER @ 104wk20 mg
NCT02792218 · Phase 3
Sustained Disability Progression 7.8% (n=944) vs 10.7% (n=932) TER @ 78wk20 mg
responder rate · % of participants
NCT02792231 · Phase 3
show 5 more results
8.1% (n=944) vs 12% (n=932) TER @ 104wk20 mg
NCT02792231 · Phase 3
8% (n=479) vs 10% (n=473) TER @ 78wk20 mg
NCT02792231 · Phase 3
8% (n=479) vs 10.9% (n=473) TER @ 104wk20 mg
NCT02792231 · Phase 3
7.8% (n=944) vs 10.7% (n=932) TER @ 78wk20 mg
NCT02792231 · Phase 3
8.1% (n=944) vs 12% (n=932) TER @ 104wk20 mg
NCT02792231 · Phase 3
Sustained Reduction of Disability 10.1% (n=749) vs 7.6% (n=724) TER @ 78wk20 mg
responder rate · % of participants
NCT02792231 · Phase 3
show 11 more results
11% (n=749) vs 8.2% (n=724) TER @ 104wk20 mg
NCT02792231 · Phase 3
11.1% (n=374) vs 8.1% (n=361) TER @ 78wk20 mg
NCT02792231 · Phase 3
12.3% (n=374) vs 8.1% (n=361) TER @ 104wk20 mg
NCT02792231 · Phase 3
5.4% (n=749) vs 4.6% (n=724) TER @ 78wk20 mg
NCT02792231 · Phase 3
5.8% (n=749) vs 4.6% (n=724) TER @ 104wk20 mg
NCT02792231 · Phase 3
10.1% (n=749) vs 7.6% (n=724) TER @ 78wk20 mg
NCT02792218 · Phase 3
11% (n=749) vs 8.2% (n=724) TER @ 104wk20 mg
NCT02792218 · Phase 3
9.1% (n=375) vs 7.1% (n=363) TER @ 78wk20 mg
NCT02792218 · Phase 3
9.7% (n=375) vs 8.2% (n=363) TER @ 104wk20 mg
NCT02792218 · Phase 3
5.4% (n=749) vs 4.6% (n=724) TER @ 78wk20 mg
NCT02792218 · Phase 3
5.8% (n=749) vs 4.6% (n=724) TER @ 104wk20 mg
NCT02792218 · Phase 3
T1 Gadolinium Enhancing Lesion 0.0317 vs 0.5172 TER per scan20 mg
event count · per scan
NCT02792231 · Phase 3
show 1 more result
0.067 vs 1.0413 placebo per scan @ 24wk20 mg
NCT03249714 · Phase 2 · registry result, not featured evidence
Annualized New or Enlarging T2 Lesion 0.94 vs 4.41 TER per year @ 52wk20 mg
event rate · per year
NCT02792231 · Phase 3
show 6 more results
0.72 vs 3.72 TER per year @ 104wk20 mg
NCT02792231 · Phase 3
0.13 vs 3.84 TER per year20 mg
NCT02792231 · Phase 3
1.13 vs 4.3 TER per year @ 52wk20 mg
NCT02792218 · Phase 3
0.72 vs 3.21 TER per year @ 104wk20 mg
NCT02792218 · Phase 3
0.05 vs 3.73 TER per year20 mg
NCT02792218 · Phase 3
3.7344 vs 13.1533 placebo per year @ 24wk20 mg
NCT03249714 · Phase 2 · registry result, not featured evidence
Annualized New or Enlarging T2 Lesion 0.64 vs 4.16 TER per year20 mg
event rate · per year
EOS n=448,442
NCT02792231 · Phase 3
Brain Volume Loss -0.29% (n=437) vs -0.35% (n=433) TER20 mg
percent change · % of baseline
NCT02792231 · Phase 3
show 1 more result
-0.28% (n=418) vs -0.35% (n=408) TER20 mg
NCT02792218 · Phase 3
Relapsed Subjects 16.51% (n=469) vs 32.68% (n=470) TER20 mg
responder rate · % of participants
NCT02792231 · Phase 3
SDMT Impairment 14.3% (n=930) vs 13.7% (n=917) TER @ 78wk20 mg
responder rate · % of participants
NCT02792231 · Phase 3
show 3 more results
15.4% (n=930) vs 14% (n=917) TER @ 104wk20 mg
NCT02792231 · Phase 3
14.3% (n=930) vs 13.7% (n=917) TER @ 78wk20 mg
NCT02792218 · Phase 3
15.4% (n=930) vs 12.4% (n=917) TER @ 104wk20 mg
NCT02792218 · Phase 3
Clinical Worsening 20.5% (n=941) vs 21.7% (n=930) TER @ 78wk20 mg
responder rate · % of participants
NCT02792231 · Phase 3
show 3 more results
21.4% (n=941) vs 22.6% (n=930) TER @ 104wk20 mg
NCT02792231 · Phase 3
20.5% (n=941) vs 21.7% (n=930) TER @ 78wk20 mg
NCT02792218 · Phase 3
21.4% (n=941) vs 22.6% (n=930) TER @ 104wk20 mg
NCT02792218 · Phase 3
SDMT 1.02 vs 0.64 TER score @ 26wk20 mg
absolute change · score
NCT02792231 · Phase 3
show 9 more results
1.82 vs 1.7 TER score @ 52wk20 mg
NCT02792231 · Phase 3
2.84 vs 2.05 TER score @ 78wk20 mg
NCT02792231 · Phase 3
3.5 vs 2.39 TER score @ 104wk20 mg
NCT02792231 · Phase 3
3.53 vs 2.97 TER score @ 130wk20 mg
NCT02792231 · Phase 3
1.02 vs 0.64 TER score @ 26wk20 mg
NCT02792218 · Phase 3
1.82 vs 1.7 TER score @ 52wk20 mg
NCT02792218 · Phase 3
2.84 vs 2.05 TER score @ 78wk20 mg
NCT02792218 · Phase 3
3.5 vs 2.39 TER score @ 104wk20 mg
NCT02792218 · Phase 3
2.97 vs 2.97 TER score @ 130wk20 mg
NCT02792218 · Phase 3

+ 26 further endpoints in the CSV export.

The full competitive landscape for each asset (every same-race competitor with aligned evidence, sortable) is on the asset pages: ABP 692's landscape · Ofatumumab's landscape